Pharmasaga
About Us
Pharmasaga was founded in January 2021 as a spin-off startup from Academia Sinica, leveraging over 10 years of research results from the laboratory of Dr. Wen-Ching Yang. Specifically, PS1 research is the company's core technology.
PS1 is a small-molecule inhibitor of PDIA4, a protein that plays a pivotal role in the development of diabetes. Mouse data indicate that inhibiting PDIA4 with PS1 can prevent pancreatic beta-cell death, stabilize blood glucose and glycated hemoglobin (HbA1c) levels, reduce oxidative stress in beta-cells, and even reverse diabetes.
Pharmasaga Competes in the Championship round at the BIO International Convention Start-up Stadium
The BIO International Convention (US BIO) is amajor global event on the biotechnology and pharmaceutical sector calendar, bringing together top pharmaceutical companies, biotech startups, and investors from around the world. The convention offers extensive business collaboration opportunities, particularly in licensing, technology transfer, and clinical partnerships.
We are highly honored to be selected once again for the Start-up Stadium, a competition specifically designed for global biotech startups, which aims to discover companies with breakthrough innovation and technology. Out of the 57 teams selected globally, we are one of only two teams chosen from Asia.
Please refer to Join Pharmasaga → for job details.
Pharmasaga was established in January 2021 as a spin-off startup from Academia Sinica.
Pharmasaga's core technology originates from a drug development platform and a first-in-class small-molecule drug candidate (PS1) for diabetes studied in the laboratory of Dr. Wen-Ching Yang at Academia Sinica. Pharmasaga is currently preparing to conduct clinical trials for PS1 as a treatment intended to reverse diabetes.
Pharmasaga's vision is to develop entirely new disease targets and first-in-class diabetes drugs, offering patients the opportunity to cure the disease and significantly reduce the suffering of diabetic patients, as well as the medical and financial burden on families and society.
Products
Core Technology
Academia Sinica first discovered and identified the novel diabetes target PDIA4, which regulates pancreatic beta-cell failure and diabetes progression. Using a molecular docking platform for screening, a lead compound that inhibits PDIA4 was identified from a library of hundreds of compounds. After a series of optimization and selection processes, PS-001 was chosen as the drug candidate for development into a first-in-class small-molecule drug for the diabetes market.
Our company has obtained a global exclusive license for the technology mentioned above from Academia Sinica, establishing it as the core technology for our drug development.
News
- [NEWS] New Force in New Drug Stocks! Pharmasaga to List on Emerging Stock Market on the 27th at Reference Price of NT$120
- [NEWS] Pharmasaga's Innovative Drug for Type 1/2 Diabetes Plans Phase II, Creates Buzz Ahead of Emerging Stock Listing
- [NEWS] Pharmasaga Wins 2025 Taipei Biotech Award - Innovative Technology Award
- [NEWS] Pharmasaga Competes for the North America BIO Convention Startup Competition Championship
- [2025] Pharmasaga's Innovative Diabetes Drug PS1 Demonstrates Curative Potential, Initiates Taiwan-US Clinical Trials
- [2025] Taiwan Participates in BIO 2025 North America Biotech Exhibition: Dual Focus on All-Age Healthcare Layout and International Connections
Contact Us
- Pharmasaga
- Phone number : + 886-2-27938665
- E-mail : contact@pharmasaga.com
- Address : 22 F.-1, No. 93, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221416, Taiwan (R.O.C.)